Description

The AABB Donor History Task Force is charged with the preparation and maintenance of the full-length and abbreviated DHQs and accompanying materials for compliance with FDA’s regulation and recommendations, including the Blood Donor Education Material, Medication Deferral List (MDL), vCJD Countries of Risk, Flow Charts and User Brochure. This is an ever evolving process that involves the incorporation of updated FDA guidance recommendations, AABB Standards requirements and user feedback. In this session, members of the AABB Donor History Task Force will cover major recent and expected changes to the DHQ by presenting the following: 

• A summary of donor eligibility requirements for individuals taking PrEP/PEP/ART and the reasoning behind the addition of these requirements to the DHQ and MDL. 
• An update on gender identity and screening of non-binary and transgender blood donors. 
• An overview of major changes expected with version 3.0 of the DHQ.
  

Learning Objectives:

• Summarize expected changes to the Donor History Questionnaire (DHQ) in version 3.0 and how member-center feedback from implementation of DHQ v2.0 informed revisions to specific screening questions for improved donor comprehension and ease of use.
• Summarize donor eligibility requirements for individuals taking medication for the prevention or treatment of HIV known as PrEP/PEP/ART and understand the reasoning for those requirements.
• Describe the latest developments in screening of non-binary and transgender blood donors.

Speaker(s):

• Dr. Geoffrey A. Belanger, MPH, Performance Improvement Analyst, Stanford Blood Center
• Dr. Yvette M. Miller, MD, Executive Medical Officer, American Red Cross
• Dr. Sheila F. O'Brien, PhD RN, Canadian Blood Services

Disclosures

• Geoffrey Belanger, MPH : Nothing to disclose
• Yvette Miller, MD : Nothing to disclose
• Sheila O'Brien, PhD RN : Nothing to disclose